Full-Time

Manager – Cell Therapy Manufacturing

Confirmed live in the last 24 hours

Cellares

Cellares

201-500 employees

Develops and manufactures cell therapies efficiently

Industrial & Manufacturing
Biotechnology

Compensation Overview

$90k - $210kAnnually

Senior, Expert

San Bruno, CA, USA

Category
Genomics
Biology Lab & Research
Biology & Biotech

You match the following Cellares's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor's degree in science, engineering, or related field required
  • A minimum of 8+ years of operations experience within a cGMP environment in the biotech/biopharma industry with a minimum of 3 years leadership experience. Cell/Gene Therapy experience required, CDMO experience preferred
  • Experience in tech transfer, process validation, project management, and change management
  • Previous experience interacting directly with the FDA and other regulatory agencies. Substantial knowledge of Quality Systems, GMP, FDA, GAMP, ISO and other applicable standards
  • Demonstrated experience in managing GMP manufacturing operations
  • Demonstrated startup experience or leading organizations through dramatic growth
  • Ability to build strong partnerships and effectively integrate with external collaborators to drive projects/programs forward in a matrixed environment
  • Must be able to manage shifting priorities to meet critical deadlines in a fast paced and dynamic, growing environment, while providing clear direction to team members
  • Develop and build cohesive, high performing teams with a strong sense of mission, providing training and mentoring to build sufficient management depth throughout the organization and ensure strong succession planning
  • Strong analytical, problem solving and critical thinking skills and the ability to lead as a change agent to promote flexibility, creativity, and accountability
  • Excellent teamwork and interpersonal skills with ability to influence and build strong working relationships at all levels within the organization
  • Desire to be part of a rapidly evolving organization, with compelling technology, and take products and processes to the next level
  • Experience with Operational Excellence and/or Lean Manufacturing. Lean Six Sigma certification preferred
  • Excellent organizational and communication skills
  • Self-awareness integrity, authenticity, and a growth mindset
Responsibilities
  • Lead, direct, coach, and develop an effective manufacturing team responsible for daily clinical and production of autologous and allogeneic cell therapy products, while ensuring safe and compliant operations according to cGMP requirements
  • Provide technical and managerial leadership by effectively interfacing and collaborating with key stakeholders and functions across the organization to successfully manufacture and disposition products to patients in a timely manner
  • Monitor, and improve production metrics related to Safety, Quality, Compliance, Cost, Delivery, and People
  • Oversee the hiring, development, and performance management of staff within manufacturing
  • Lead and actively participate in all health authority, customer, and internal audits of the facility
  • Serve as the Manufacturing Host for audits by leading tours and serving as SME for the facility
  • Work closely with other functional areas to develop and execute against the strategic plan for the manufacturing site
  • Establish key stakeholder relationships with internal and external stakeholders
  • Review in-process and completed documents for accuracy and to make sure batch records are turned in to area management within specified days of completion
  • Responsible for revising and originating production records, standard operating procedures, protocols and reports
  • Initiate, investigate, and support the closure of Deviation Reports and CAPAs
  • Ensure manufacturing processes in both an R&D and GMP environments are following appropriate protocols and/or standard operating procedures (SOPs)
  • Provide feedback to engineering and process teams, support with requirements gathering and review
  • Contribute to analysis and presentation of technical results at departmental meetings and with clients
  • Perform routine clean room and laboratory activities including ordering, cleaning, restocking, and equipment qualification/maintenance
  • Work with Quality Control, Facilities, Materials Management, Quality Assurance and Validation to complete assignments
  • Other duties as assigned
Desired Qualifications
  • CDMO experience preferred
  • Lean Six Sigma certification preferred

Cellares develops and manufactures cell therapies in the biotechnology sector. It operates as an Integrated Development and Manufacturing Organization (IDMO), which means it combines the development and manufacturing processes of cell therapies in one facility. This approach is different from traditional Contract Development and Manufacturing Organizations (CDMOs) that keep these processes separate. Cellares utilizes its proprietary "Smart Factory" technology, which includes an automated single-use cartridge system. This technology significantly boosts productivity, reduces costs, and lowers process failure rates compared to conventional methods. The company serves a variety of clients, including those in preclinical, clinical, and commercial stages, and has partnered with major pharmaceutical companies to enhance the manufacturing of CAR-T cell therapies. Cellares aims to provide efficient and cost-effective solutions for cell therapy development and manufacturing.

Company Size

201-500

Company Stage

Series C

Total Funding

$345.3M

Headquarters

South San Francisco, California

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • Strategic partnerships with Bristol Myers Squibb enhance market validation and scaling potential.
  • The launch of Cell Q automates QC for 6,000 batches, boosting efficiency.
  • Cellares' global expansion is supported by experienced leaders like Ossama Eissa and Christi Shaw.

What critics are saying

  • Rapid Smart Factory expansion may lead to operational and quality control challenges.
  • Technological integration with Sony could delay Cell Shuttle platform deployment.
  • Reliance on strategic partnerships exposes Cellares to partners' financial and operational risks.

What makes Cellares unique

  • Cellares' Cell Shuttle offers 10x scalability over manual cell therapy manufacturing.
  • The company is the first Integrated Development and Manufacturing Organization (IDMO) in cell therapy.
  • Cellares' Smart Factory technology reduces costs by 50% and failure rates by 75%.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

2%
ROI-NJ
Nov 13th, 2024
Cellares appoints former Novartis, Lonza and Legend Biopharma exec as COO

Cellares, a Bridgewater-based leader in automated cell therapy manufacturing, on Monday announced it appointed Ossama Eissa, former executive at Novartis, Lonza Biologics, and Legend Biotech, as chief operating officer.

ROI-NJ
Nov 13th, 2024
Cellares Appoints Former Novartis, Lonza And Legend Biopharma Exec As Coo

Cellares, a Bridgewater-based leader in automated cell therapy manufacturing, on Monday announced it appointed Ossama Eissa, former executive at Novartis, Lonza Biologics, and Legend Biotech, as chief operating officer.Eissa’s extensive experience will support the expansion of Cellares’ Smart Factory network in the United States, Europe, Japan and other international markets, addressing the challenges of scalability, cost, and quality that have long hindered patient access. Through these advancements, Cellares will work to ensure that life-saving treatments are accessible for oncology and autoimmune patients globally.This appointment strengthens the Cellares leadership team in a time of rapid global expansion of the company’s IDMO manufacturing services, in response to the growing global demand for cell therapy manufacturing capacity.Eissa brings more than 20 years of experience in pharmaceutical and biotech manufacturing.He formerly served as vice president and general manager at Legend Biotech, where he led the Raritan production site through the global launch of Carvykti, a CAR-T cell therapy.At Lonza Biologics, Eissa managed Global Strategic Projects, contributing significantly to the Cell and Gene Technologies Business Unit by boosting manufacturing efficiency and driving commercial scale-up. He also oversaw U.S. manufacturing operations at Novartis, scaling production and supporting regulatory approval for Kymriah, the first FDA-approved CAR-T cell therapy.“Joining Cellares is an opportunity to address one of the biggest challenges in healthcare today: making cell therapies accessible to all of those who need them,” Eissa said. “The mission aligns closely with my experience in scaling complex manufacturing systems to benefit patients directly. I’ve witnessed the profound impact these treatments have, and I’m committed to ensuring that we reach more patients, especially those facing cancer and autoimmune diseases, with the reliability and speed they deserve.”

BioProcess International
Sep 12th, 2024
Cellares and Sony partner to automate cell therapy manufacturing

Self-acclaimed integrated development and manufacturing organization (IDMO) Cellares has partnered with Sony Corporation, a technology firm focused on the field of flow cytometry, to integrate advanced flow cytometry-based cell analysis and sorting solutions into the Cellares Cell Shuttle platform.

Contract Pharma
Sep 3rd, 2024
Cellares Appoints CFO and General Counsel

Cellares, a leader in cell therapy manufacturing and an Integrated Development and Manufacturing Organization (IDMO), has appointed Justin McAnear as Chief Financial Officer (CFO) and Jonathan Butler as General Counsel and Corporate Secretary (GC).

Business Wire
Apr 22nd, 2024
Bristol Myers Squibb And Cellares Announce A $380M Worldwide Capacity Reservation And Supply Agreement For The Manufacture Of Car T Cell Therapies To Bring The Promise Of Cell Therapy To More Patients, Faster

PRINCETON, N.J. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, today announced a worldwide capacity reservation and supply agreement for the manufacture of CAR T cell therapies in a transaction valued up to $380M in upfront and milestone payments. As part of the agreement, Cellares will optimize, automate, and tech-transfer select Bristol Myers Squibb CAR T cell therapies onto its automated and high-throughput manufacturing platform, the Cell Shuttle™. Cellares will dedicate multiple Cell Shuttle and Cell Q™ systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use. The Cell Shuttles and Cell Qs will be deployed in Cellares’ Smart Factories in the U.S., EU, and Japan. Manufacturing cell therapies is both operationally and technically complex